A case-control study investigating the association of TP53 rs1042522 and CDH1 rs16260 polymorphisms with prostate cancer risk
Date
2021
Authors
Akter, R.
Islam, M.S.
Islam, M.S.
Aziz, M.A.
Hussain, M.S.
Millat, M.S.
Uddin, M.S.
Islam, M.S.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Meta Gene, 2021; 30(100962):1-6
Statement of Responsibility
Conference Name
Abstract
Objectives: Prostate cancer is the most frequent non-cutaneous malignancy in men. Numerous genetic factors play a crucial role in the progression of prostate cancer. This study was undertaken to reveal the correlation of TP53 rs1042522 and CDH1 rs16260 polymorphisms with the risk of prostate cancer in the Bangladeshi population. Materials and methods: We recruited 210 prostate cancer patients and 210 healthy controls for the investigation. Genotyping was conducted using the PCR-RFLP technique. Results: In case of TP53 gene rs1042522, the association analysis revealed that all genetic models were linked with significantly increased risk for prostate cancer development (CG vs. CC: OR = 1.99, p = 0.001; GG vs. CC: OR = 4.82, p < 0.00; CG vs. CC + GG: OR = 1.52, p = 0.041; CG + GG vs. CC: OR = 2.44, p < 0.00; GG vs. CC + CG: OR = 3.64, p = 0.00; G vs. C: OR = 2.32, p < 0.00). Again, the second variant rs16260 in CDH1 gene also showed significantly enhanced association in all genetic models for the development of prostate cancer (CA vs. CC: OR = 2.20, p < 0.00; AA vs. CC: OR = 2.77, p = 0.012; CA vs. CC + AA: OR = 1.98, p = 0.001; CA + AA vs. CC: OR = 2.29, p = 0.00; A vs. C: OR = 1.99, p < 0.00) except the AA vs. CC + CA model. Conclusions: Our study indicates a significant association of TP53 rs1042522 and CDH1 rs16260 polymorphisms with increased prostate cancer risk in the Bangladeshi population. However, replication studies are required in different populations to validate our findings.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2021 Elsevier